Does urinary detection of gliotoxin or mycophenolic acid identify the exposure source or explain neurological symptoms?

Gliotoxin and mycophenolic acid have credible immunobiologic effects, but a urinary result is not equivalent to a clinically interpretable exposure dose, source attribution, or explanation for neurological illness.

Mechanisms and immune effects

• Gliotoxin disrupts redox regulation in experimental immune-cell systems. In THP-1 macrophages, 50 ng/mL increased intracellular reactive oxygen species and NOX2-complex components while reducing glutathione; 25 ng/mL did not produce measurable oxidative-stress changes. Its reactive disulfide chemistry permits thiol–disulfide exchange and glutathione-dependent redox cycling.
• Gliotoxin also suppresses immune functions in vitro, including macrophage phagocytosis and TNF-α secretion, antigen-driven lymphocyte stimulation, cytotoxic-T-cell activation, and CD4-cell interferon-γ production. Primary human lymphocyte growth inhibition was concentration-dependent—approximately 18–21% at low concentrations and 85–87% at 200 ng/mL.
• Mycophenolic acid (MPA) selectively and reversibly inhibits IMPDH, blocking IMP-to-XMP conversion and de novo guanosine-nucleotide synthesis. Activated T and B cells rely substantially on this pathway; nucleotide depletion limits DNA synthesis, cell division, B-cell differentiation, and antibody production. Guanosine reverses the antiproliferative effect, supporting this mechanism.

Interpretation of urine testing and neurological symptoms

• A urinary gliotoxin measurement does not identify an indoor-mold or inhalational source; diet, timing, urine dilution, and poorly resolved human toxicokinetics preclude source attribution. For MPA, extensive glucuronidation and renal handling—unchanged MPA is <1% of an administered dose—also make urine results unsuitable for identifying source.
• Neither analyte’s urinary detection proves neurological causation. There are no validated urine concentration–neurological outcome relationships for gliotoxin or MPA. MPA-associated neurological syndromes such as PRES, PML, or CNS infection require clinical evaluation, not inference from urine testing.

Bottom line

• The claim is well supported overall: both compounds have biologically plausible immune effects, but urine detection alone cannot establish source or causation of neurological symptoms.